Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours.
Eur J Cancer
; 32A(13): 2360-3, 1996 Dec.
Article
in En
| MEDLINE
| ID: mdl-9038623
ABSTRACT
In breast cancers and sarcomas, a variant polymorphism in the cell cycle inhibitor P21CIP1/WAF1 is under-represented in those individuals whose tumours contain mutated TP53. The aim of this study was to determine whether this variant polymorphism was also under-represented in those with ovarian carcinoma and TP53 mutations. We studied lymphocyte DNA from 104 women with ovarian carcinoma, 15 with borderline tumours and 16 with benign tumours, using a previously-reported PCR-RFLP technique. 96 of the ovarian carcinoma cases had been previously examined for mutations in TP53 and/or for overexpression of the TP53 protein. The variant allele was seen in 11 out of 104 women (10.6%) with ovarian carcinoma. There was no significant difference in the distribution of the variant allele in the women whose tumours had (7/47) or did not have (4/49) TP53 mutations (P = 0.523). It does not appear that the presence of this variant allele of P21CIP1/WAF1 has any aetiological role in ovarian carcinomas. Studies in other tumours support this finding.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Ovarian Neoplasms
/
Polymorphism, Genetic
/
Genes, p53
/
Cyclins
/
Enzyme Inhibitors
Limits:
Female
/
Humans
Language:
En
Journal:
Eur J Cancer
Year:
1996
Document type:
Article
Affiliation country:
United kingdom